Enhancement of experimental cutaneous leishmaniasis by Leishmania extract: identification of a disease-associated antibody specificity

BMC Research Notes

Lain Pontes–de-Carvalho²  Pablo R. S. Oliveira¹  Isabela C. Navarro¹  Cíntia F. de-Araújo¹  Virgínia M. G. Silva³ 

[1]Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador 40296-710, BA, Brazil

[2]Escola Bahiana de Medicina e Saúde Pública, Salvador 40050-420, BA, Brazil

[3]Universidade Estadual do Sudoeste da Bahia, Departamento de Ciências Biológicas, Jequié 45206-190, BA, Brazil

关键词: Disease progression;    Antibody response;    Leishmania;   

Others  :  1232458
DOI  :  10.1186/s13104-015-1158-0

 received in 2014-06-04, accepted in 2015-04-30,  发布年份 2015

【 摘 要 】

Background

Both Leishmania braziliensis and Leishmania amazonensis induce cutaneous disease when injected in the skin of BALB/c mice. However, L. amazonensis may also visceralize in that strain of mice, infecting mainly the liver and spleen. In addition, whereas BALB/c mice die with a progressive cutaneous disease when infected by L. amazonensis, the infection by L. braziliensis is spontaneously cured. In a previous work, we have found that intravenous injections of L. amazonensis amastigote extract (LaE) potentiated a L. braziliensis infection in BALB/c mice, and that this infection-promoting activity could be inhibited by the addition of protease inhibitors to the extract.

Methods

In order to detect markers of disease evolution, in the present work we analyzed the specificity of the anti-L. amazonensis antibody response of L. braziliensis-infected BALB/c mice injected intravenously with saline or LaE, supplemented or not with protease inhibitors, by the Western blot technique.

Results

IgG1 antibodies recognizing an antigen with apparent molecular weight of 116 kDa were specifically detected in BALB/c mice that had been turned susceptible to L. braziliensis infection by injections of LaE.

Conclusion

A Th2 immune response (IgG1 antibody-producing) against this 116 kDa antigen, therefore, could be associated with susceptibility to severe Leishmania infection.

【 授权许可】

   
2015 Silva et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Almeida RP, Barral-Neto M, de Jesus AMR, de Freitas LAR, Carvalho EM, Barral A: Biological behavior of Leishmania amazonensis isolated from humans with cutaneous, mucosal, or visceral leishmaniasis in BALB/c mice. Am J Trop Med Hyg 1996, 54:178-84.
• [2]Handman E: Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001, 14:229-43.
• [3]Leopoldo PT, Machado PR, Almeida RP, Schrifer A, Giudice A, de Jesus AR, et al.: Differencial effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production. BMC Infect Dis 2006, 25:75-80. BioMed Central Full Text
• [4]Davidson RN: Visceral leishmaniasis in clinical practice. J Infect 1999, 2:112-6.
• [5]Belli AA, Milles MA, Kelly JM: A putative Leishmania panamensis/Leishmania braziliensis hybrid is a causative agent of human cutaneous leishmaniasis in Nicaragua. Parasitology 1994, 109:435-42.
• [6]Grimaldi G Jr, Tesh RB: Leishmaniases of the New World: current and implications for future research. Clin Microbiol 1993, 6:230-50.
• [7]Williams KM, Sacci JB, Anthony RL: Identification and recovery of Leishmania antigen displayed on the surface membrane of mouse peritoneal macrophages infected in vitro. J Immunol 1986, 136:1853-8.
• [8]Silveira TG, Kemmelmeier C: Leishmania braziliensis: isolation of carbohydrate-containing antigen and possibility of its use in the immunodiagnosis of American cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo 1995, 37:245-52.
• [9]Carmelo E, Martinez E, González AC, Piñero JE, Patarroyo ME, Del Castillo A, et al.: Antigenicity of Leishmania braziliensis histone H1 during cutaneous leishmaniasis: localization of antigenic determinants. Clin Diag Lab Immunol 2002, 9:808-11.
• [10]Petersen EA, Neva FA, Oster CN, Dias HB: Specific inhibition of lymphocyte proliferation responses by adherent suppressor cells in diffuse cutaneous leishmaniasis. N Engl J Med 1982, 306:387-92.
• [11]Castes M, Agnelli A, Verde O, Rondon AJ: Characterization of the cellular immune response in American cutaneous leishmaniasis. Clin Immunol Immunopathol 1983, 27:176-86.
• [12]Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL: Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-8.
• [13]Maekawa Y, Himeno K, Ishikawa H, Hisaeda H, Sakai T, Dainichi T, et al.: Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. J Immunol 1998, 161:2120-7.
• [14]Alexander J, Blackwell JM: The immunological significance of genetically determined cross reactivity between taxonomically distinct Leishmania species. In Leishmania, taxonomie et phylogenèse: application éco-épidemiologiques . Edited by Riou JA. Institut Méditerranéen d’Etudes Epidémiologiques et Ecologiques, Montpellier; 1986:185-91.
• [15]Afonso LC, Scott P: Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993, 61:2952-9.
• [16]Lemos LV, Ascenção SJ, Correia STM, Sampaio TVP, Rodrigues-de-Freitas LA: Different Leishmania species determine distinct profiles of immune and histopathological responses in CBA mice. Microbes Infect 2000, 2:1807-15.
• [17]Souza VL, Veras PS, Welby-Borges M, Silva TM, Leite BR, Ferraro RB, et al.: Immune and inflammatory responses to Leishmania amazonensis isolated from different clinical forms of human leishmaniasis in CBA mice. Mem Inst Oswaldo Cruz 2011, 106:23-31.
• [18]Mary C, Lamouroux D, Quilici M: Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kDa and 16-kDa antigens for diagnosis and epidemiologic purpose. Am J Trop Med Hyg 1992, 47:764-71.
• [19]Burns JJM, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG: Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A 1993, 90:775-9.
• [20]Badaró R, Benson D, Eulálio MC, Freire M, Cunha S, Netto EM, et al.: rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996, 173:758-61.
• [21]De Krey GK, Lima HC, Titus RG: Analysis of the immune response of mice infection with Leishmania braziliensis. Infec Immun 1998, 66:827-9.
• [22]Silva VM, Larangeira DF, Oliveira PR, Sampaio RB, Suzart P, et al.: Biointervention Student Group: Enhancement of experimental cutaneous leishmaniasis by leishmania molecules with serine protease activity. I. Requirement of IL-4. Infect Immun 2011, 79:1236-43.
• [23]Teixeira MC, De-Jesus SR, Sampaio RB, Pontes-De-Carvalho LC, Dos-Santos WC: A sample and reproducible method to obtain large numbers of axenic amastiotes of different Leishmania species. Parasitol 2002, 88:963-8.
• [24]Lowry OH, Rosenbrough NJ, Faar AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193:265-75.
• [25]Lima HC, Bleyenberg JA, Titus RG: A simple method for quantifying Leishmania in tissues of infected animals. Techniques 1997, 13:80-2.
• [26]Laemmli UK: Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-5.
• [27]Reiner SL, Locksley RM: The regulation of immunity to Leishmania major. Ann Rev Immunol 1995, 13:151-77.
• [28]Bogdan C, Rollinghoff M: The immune response to Leishmania: mechanisms of parasite control and evasion. Intern J Parasit 1998, 28:121-34.
• [29]Hassani K, Olivier M: Immunomodulatory impact of Leishmania-induced macrophage exosomes: a comparative proteomic and functional analysis. PLoS Negl Trop Dis 2013., 7Article ID e2185
• [30]de Araújo CF, Silva VM, Cronemberger-Andrade A, Aragão-França LS, Rocha VC, Santos PS, et al.: Leishmania braziliensis and Leishmania amazonensis amastigote extracts differ in their enhancement effect on Leishmania infection when injected intradermally. BMC Res Notes 2014, 7:70. BioMed Central Full Text
• [31]de Matos Guedes HL, Pinheiro RO, Chaves SP, De-Simone SG, Rossi-Bergmann B: Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine. Vaccine 2010, 28:5491-6.
• [32]Lacerda ID, Cysne-Finkelstein L, Nunes PM, De-Luca PM, Genestra SM, Leon PLL, et al.: Kinetoplastid membrane protein-11 exacerbates infection with Leishmania amazonensis in murine macrophages. Mem Inst Oswaldo Cruz 2012, 107:238-45.
• [33]Julia V, Rassoulzadegan M, Glaichenhaus N: Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996, 274:421-3.
• [34]Srivastava S, Pandey SP, Jha MK, Chandel HS, Saha B: Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses. Clin Exp Immunol 2013, 172:403-9.
• [35]Gómez MA, Olivier M: Proteases and phosphatases during Leishmania-macrophage interaction: paving the road for pathogenesis. Virulence 2010, 1:314-8.
• [36]Silva-Lopez RE, Coelho MG, De-Simone SG: Characterization of an extracellular serine protease of Leishmania (Leishmania) amazonensis. Parasitol 2005, 131:85-96.